Navigation Links
CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting
Date:5/21/2017

CNSDose is a genetically driven, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. It can also strengthen the doctor-patient relationship through a personalized approach to treatment.

A peer-reviewed and published, 12-week double-blind randomized controlled trial (RCT) that compared genetically guided and unguided antidepressant prescribing demonstrated positive results. The trial showed 72% of patients experienced full symptom recovery when using CNSDose compared to 28% of patients using trial and error. A recent review undertaken by the Department of Veterans Affairs Health Administration noted that, “CNSDose has the most favorable preliminary findings.” The CNSDose RCT was followed by another independent study, also peer-reviewed, that supported the RCT and showed > 85% accuracy, sensitivity, and specificity.

“We are thrilled to participate in the American Psychiatric Association Annual Meeting,” said Mark Heinemeyer, CEO of CNSDose. “This is where the leaders in psychiatry gather to learn and share new approaches – a perfect venue for us!”

Ajeet Singh MD PhD, Founder and Chief Science Officer of CNSDose, was recently published in The Journal of Precision Medicine in an editorial entitled Antidepressant Pharmacogenetics (Singh, Ajeet, & Bousman, Chad (2017). Antidepressant Pharmacogenetics. The Journal of Precision Medicine, 174:5, 417-418.). This editorial points to the impact that this type of testing can have, “…it is important for clinicians to keep abreast of this evolving area to best facilitate informed discussions with patients….genetically guided antidepressant prescribing may become part of routine clinical practice.”

Chief Medical Officer of CNSDose, Harris Eyre MD PhD, will be presenting at a symposium at the APA Annual Meeting. Representatives for CNSDose will be available at booth #2223. Advance meetings may be scheduled by calling 888.858.6285 x 2.

About CNSDose

CNSDose is a genetically driven, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. According to a review undertaken by the Department of Veterans Affairs on pharmacogenomics-guided antidepressant treatment, “CNSDose has the most favorable preliminary findings.” For more information, please visit: https://www.cnsdose.com/

Read the full story at http://www.prweb.com/releases/2017/05/prweb14353739.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Thermo Fisher Scientific Demonstrates Improved differentiation of Stem Cell-derived Neurons and Downstream Applications
2. PathSensors Demonstrates Breakthrough Mail Security Screening Solution at National Postal Forum 2017
3. BESI Full Scale Advanced Gasification Research Facility in University Park, Il Demonstrates Clean Waste Conversion for US Military
4. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
5. Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
6. Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
7. Clinical Utility of Biocepts Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
8. ProMetics PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial
9. New Clinical Study Demonstrates Feasibility of Performing Multiplex ANA Testing on Whole Blood via Finger-Stick in Physician Office Near-Patient Setting
10. Bird Rock Bios Gerilimzumab, an Anti-IL-6 Antibody, Demonstrates Potential for Affordable Global Access to a Novel Biologic to Treat Rheumatoid Arthritis
11. New Persephone Technology to Be Demonstrated at Genome Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):